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Abstract
Introduction: Few studies have performed expression profiling of both miRNA and mRNA from the same primary breast
carcinomas. In this study we present and analyze data derived from expression profiling of 799 miRNAs in 101 primary
human breast tumors, along with genome-wide mRNA profiles and extensive clinical information.
Methods: We investigate the relationship between these molecular components, in terms of their correlation with each
other and with clinical characteristics. We use a systems biology approach to examine the correlative relationship between
miRNA and mRNAs using statistical enrichment methods.
Results: We identify statistical significant differential expression of miRNAs between molecular intrinsic subtypes, and
between samples with different levels of proliferation. Specifically, we point to miRNAs significantly associated with TP53
and ER status. We also show that several cellular processes, such as proliferation, cell adhesion and immune response, are
strongly associated with certain miRNAs. We validate the role of miRNAs in regulating proliferation using high-throughput
lysate-microarrays on cell lines and point to potential drivers of this process.
Conclusion: This study provides a comprehensive dataset as well as methods and system-level results that jointly form a
basis for further work on understanding the role of miRNA in primary breast cancer.
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Introduction
Expression profiling of mRNA has been used to molecularly
characterize various tissues and tumors. A range of gene signatures
that predicts pathway activation, has been identified in various
cancer types (reviewed in [1]). In breast cancer, mRNA profiling
has been used to classify breast tumors and associate them with
clinical and pathological characteristics as well as with prediction
of outcome [2,3,4,5]. In particular, luminal-A and basal-like
subtypes, defined using an intrinsic gene list, have distinct and
reciprocal gene expression profiles as well as large differences in
clinical characteristics, including survival [5,6,7,8].
Gene expression regulation through mechanisms that involve
microRNAs (miRNAs) has attracted much attention during recent
years. miRNAs are a class of endogenous small regulatory RNA
molecules that target mRNAs and trigger either translation
repression or mRNA degradation [9]. There are to date more
than 900 identified human miRNAs [10], transcribed as individual
units, polycistronic clusters or in concert with a protein coding host
gene [11]. Many miRNAs regulate genes associated with different
biological processes such as development, proliferation, apoptosis,
stress response, and tumourigenesis [12,13,14,15,16].
Abnormal expression levels of several miRNAs have previously
been shown to be associated with multiple cancer types including
breast cancer [17,18,19,20]. Some miRNAs correlate with specific
clinical features of breast cancer, such as estrogen and progester-
one receptor expression, tumor stage, vascular invasion, and
proliferation index [19,21,22,23]. In a study by Blenkiron et al. a
set of 309 miRNAs were profiled in 93 human primary breast
tumors, 5 normal breast samples and 21 cell lines, identifying 31
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16915miRNAs associated with molecular subtype, estrogen receptor
status or grade [24]. In addition, this study reported a strong co-
regulation of miRNA genomic clusters and showed that for the
majority of miRNAs differential expression cannot be attributed to
chromosomal loss or gain in their genomic region. The study
reports some findings that pertain to jointly analyzing the miRNA
data with its matching mRNA data. Continuing this direction and
taking a systematic approach to joint analysis will further enhance
our understanding of the role of miRNA in breast cancer
pathogenesis and progression.
In this work we present expression profiling of 799 miRNAs in
101 human primary breast tumor samples, along with genome-
wide matched mRNA profiling and extensive clinical information.
We applied several approaches to statistically analyze the resulting
data. We identified statistically significant differential expression of
miRNAs that distinguishes the reciprocal basal-like and luminal-A
breast cancer subtypes. Our analysis confirmed some observations
from previous studies including Blenkiron et al. [24], but also
revealed subtype specific expression of previously uncharacterized
miRNAs. We put emphasis on the joint analysis of miRNA and
mRNA data, and analyzed correlations between miRNA and
mRNA expression data. We show that particular cellular processes
such as proliferation, cell adhesion, and immune response are
significantly enriched in the co-regulated clusters, suggesting a
central role for miRNAs in regulating these pivotal pathways. We
performed functional assays using direct measurement techniques
to validate the influence of miRNA on proliferation.
Results
miRNA differential expression in molecular breast cancer
subtypes
miRNA expression profiling was carried out for 101 human
primary breast cancer samples (Table S1) using microarrays
covering 799 miRNAs, from Agilent Technologies. After filtering
miRNAs that were not expressed in most of the cohort (see
Materials and Methods), 489 miRNAs were considered for further
analyses. Applying hierarchical clustering based on the 100 most
variably expressed miRNAs, we observed a cluster consisting of
tumors with mainly basal-like subtype characterization, that was
distinguished by a higher expression of the miR-17-92 cluster/
family from 7q22.1, 13q31.3 and Xq26.2 (Figure 1A).
Since the basal-like breast cancer subtype is defined by specific
morphological and pathological characteristics as well as by a
distinct mRNA expression profile we explored the full list of
miRNAs related to the basal-like tumors. Comparing miRNA
expression in 15 basal-like and 41 luminal-A samples, the subtypes
with strongest reciprocal mRNA expression profiles, 111 differen-
tially expressed miRNAs were identified at an FDR (False
Discovery Rate [25]) of 5%. The top 26 miRNAs separated
almost perfectly the basal-like and luminal-A samples (Threshold
number of misclassification (TNoM) #6, see Materials and
Methods). These results confirm that the subtype difference is
manifested also at the level of miRNA expression (Figure 1B,
Table S2). Only five miRNAs were intronic in genes that play a
role in the mRNA subtype classification (hsa-mir-324 in ACADVL,
hsa-mir-153 in PTPRN2, hsa-mir-934 in VGLL1, hsa-mir-595 in
PTPRN2, hsa-mir-744 in MAP2K4), demonstrating that the
miRNA differential expression is not merely a recapitulation of
the mRNA classification.
The top miRNAs with elevated expression levels in basal-like
samples were miR-18a/b (TNoM p,2E-10) and other members
of the miR-17-92 cluster (miR-17/17*, miR-18a/b, miR-19a,
miR-20a and miR-106a). In addition we found miR-9/9* (TNoM
p-value , 4E-9), which had no detectable expression in most of
the non-basal-like samples (Figure S1A). Among the prominently
down regulated miRNAs in basal-like tumors were representatives
of the miR-29 family (TNoM p,7E-12) along with miR-190b
(TNoM p,2E-10) (Figure S1B-C). miR-29 family members were
moderately expressed in subtypes other than luminal-A and basal-
like. miR-190b had an almost discrete binary expression mode
with higher expression in the luminal-A/B subtypes than in the
basal-like/ERBB2-enriched subtypes (TNoM p,4E-15). We
further discuss the role of miR-29 in our cohort in later sections.
miRNA expression and TP53 mutational status
Mutations in the TP53 gene are well studied and have been
associated with cancer progression and worse prognosis [26]. In the
present cohort we explored the miRNAs that were differentially
expressed between the 64 wild-type samples (WT) and 36 TP53
mutant samples (Figure 2). Since the breast cancer subtype
classification is not independent of the TP53 status, with most of
the basal-like and ERBB2-enriched tumors having TP53 mutations,
many of the same miRNAs were found to be differentially expressed
in both partitions. At top among the 81 differentially expressed
miRNAs (at 5% FDR) we identified miR-342-3p (TNoM p , 2E-
08) to have significantly lower expression in the TP53 mutant
tumors. We note that miR-34a, previously shown to regulate TP53
[14], is not observed to be differentially expressed in comparing
TP53 mutational status in this cohort (Table S3).
As previously reported [26] there is a strong association between
estrogen receptor (ER) and TP53 status (Figure 2). Tumor samples
with wild type TP53 are mostly ER-positive and samples with
mutated TP53 are mostly ER-negative. In line with this co-
occurrence we observed a substantial overlap between miRNAs
differentially expressed between ER+ and ER- samples and
between WT and mutant TP53 samples. Removing this
confounding factor, by comparing 50 TP53 WT/ER+ samples
vs. 11 TP53 mutant/ER+ samples or 12 TP53 WT/ER- samples
vs. 26 TP53 mutant/ER- samples, we observed different
repertoires of differentially expressed miRNAs (Table S3).
Joint enrichment analysis associates miRNAs to distinct
biological processes
To better understand the role of miRNAs in different biological
modules, as evidenced in our cohort of primary breast cancer
samples, we further take a systems biology approach to examine
the correlative relationship between miRNA and mRNAs. For
each miRNA, separately taken as a pivot, the mRNA transcripts
were ranked according to the correlation of their expression
pattern to the expression pattern of the pivot miRNA. Using GO
enrichment analysis carried out on the ranked list of mRNAs (see
Materials and Methods) we were able to elucidate the biological
modules that are correlated or anti-correlated to the expression
level of the pivot miRNA (Table S4). We note that this association
does not imply a direct regulation by the miRNA but rather
indicates the biological process in which the pivot miRNA plays a
role. For several cases we are able to find an enrichment of the
pivot miRNA targets in its anti-correlated mRNAs. In these cases
we point to a potential direct regulation effect by the miRNA.
Several pivot miRNAs showed strong association to cell-cycle
genes. Specifically, we observed an enrichment of cell-cycle genes
when considering positive correlation to members of the miR-17-
92 cluster, with miR-93 and miR-18b yielding the strongest
enrichment (minimum-hypergeometric (mHG) p,E-74 and p,E-
73, respectively). In accordance with previous results [27] we also
observed a significant enrichment of genes regulated by E2F
(mHG p,E-24 and p,E-27 for the above two miRNAs,
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targets are enriched amongst its anti-correlatees (mHG p,2E-12).
For miR-493 and the miR-214 cluster we observed cell-cycle genes
to be enriched in the negatively correlated genes.
Another biological module with many significantly associated
miRNAs is that of the immune response (Table S4). In particular,
miR-150 was found to have the strongest enrichment of the
immune response term amongst its positive correlated mRNAs
(mHG p,E-147, Figure 3). In addition we identified other
miRNAs with a strong positive correlation to the immune response
module (e.g. miR-146 at mHG p,E-132, miR-142 at mHG p,E-
108, miR-155 at mHG p,E-123, and miR-223 with mHG p,E-
111). Interestingly, their association was more related to T-cell
activation genes while miR-150 was strongly associated with genes
related to the inflammatory response.
miRNA expression associated with proliferation
Our systematic approach led us to pay special attention to the
cell-cycle module in the context of our cohort of early stage breast
cancer patients. As activation of cell-cycle genes is closely related
to proliferation we further examined the expression of miRNAs in
samples with different proliferative states. To do so, we used Ki67
immunohistochemistry staining (IHC) and scoring of mitotic count
from tumor sections to partition the samples into a High-
Proliferative class (HP), consisting of 24 samples, and a Low-
Proliferative class (LP) consisting of 35 samples (Figure 4A, see
Materials and Methods). We identified 123 differentially expressed
miRNAs (at 5% FDR, Table S5) when comparing HP and LP
classes. This high number reflects the significant difference
between the miRNA expression signatures of the two classes
(Figure 4B, Table S5).
No basal-like nor luminal-B samples were assigned to the LP
class, while no luminal-A and no normal-like samples, except one,
were grouped to the HP class. However, ERBB2-enriched samples
were equally assigned to the different proliferation classes (6 in HP
and 5 in LP). To test for subtype independent miRNA differential
expression we examined differential expression using only the
ERBB2-enriched samples. We identified 21 miRNAs (at TNoM
Figure 2. miRNAs differentially expressed between TP53 WT and mutated samples. miRNAs ordered by significance of differential
expression between TP53 WT and mutant samples. Color boxes illustrate molecular subtype, and estrogen receptor status in black and white, while
gray boxes represent unclassified samples. The 16 most significant of 44 miRNAs (p,0.0001) are shown in the tables with number of misclassified
samples (TNoM), TNoM p-value, and t-test p-value. For visualization expression values of each miRNA were linearly stretched to a scale of -2.0 to 2.0.
doi:10.1371/journal.pone.0016915.g002
Figure 1. Subtype specific differential miRNA expression. (A) Hierarchical clustering of the 100 most variable (largest variance values) miRNAs
across 101 tumors with dendrograms illustrating similarities between samples/genes. The yellow box indicates members of the miR-17-92 clusters
that have higher expression in the basal-like subtype. The color in the bars beneath the heatmap illustrates the different subtypes as defined by
centroid correlation [8] and EMT classes [29]. Black boxes represent ER- and TP53 mutant samples. (B) miRNAs differentially expressed between basal-
like and luminal-A subtypes. miRNAs ordered by significance of differential expression between 15 basal-like and 41 luminal-A samples. The 26 most
significant of 77 miRNAs (p,0.0001) are shown in the tables with number of misclassified samples (TNoM), TNoM p-value, and t-test p-value. For
visualization expression values of each miRNA were linearly stretched to a scale of -2.0 to 2.0.
doi:10.1371/journal.pone.0016915.g001
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also among the differentially expressed miRNAs in the overall
comparison (Table S5). Specifically, miR-574-3p and miR-18b
ranked high in both comparisons.
Estrogen receptor (ER) status differs between the LP (6 ER-; 29
ER+) and HP (17 ER-; 7 ER+) groups. We further examined the
association of miRNAs to proliferation in the ER-negative
samples. While most miRNAs (e.g. miR-18b up-regulation and
miR-145 down-regulation) showed an ER status independent
differential expression, miR-199 and miR-214 were down-
regulated in proliferating samples only in the 38 ER-negative
samples (both with TNoM p,0.01, see Table S6).
To better understand the relation of the miRNAs to different
proliferating processes we compared the cell-cycle associations as
described above to the level of differential expression, according to
proliferation status (HP vs. LP), of the miRNAs. As would be
expected we find the miRNAs associated with cell-cycle genes to
be differentially expressed between proliferative samples and non-
proliferative samples. However, we also observe that the level of
differential expression of the miRNAs in proliferation is in
monotone relation to the level of enrichment of the cell-cycle
genes (Figure 4C). Moreover - there is a strong correlation
between the extent of miRNA over-expression in proliferative
samples and the enrichment of the GO term ‘‘positive regulation
of mitotic cell cycle’’ in its correlated genes (Pearson’s r =0.76,
Figure S2A). An opposite observation holds for the GO term
‘‘negative regulation of S phase of mitotic cell cycle’’, where
miRNAs over-expressed in the proliferative samples show
enrichment of this GO term in their anti-correlated genes
(Pearson’s r = 20.51, Figure S2B). We further analyzed all GO
terms to explore the relationship between enrichment and HP vs.
LP differential expression. The strong positive correlation
observed in Figure 4C for the cell-cycle module is not attained
by any other GO term.
Functional characterization of proliferative miRNAs
In order to indentify miRNAs that potentially drive the
proliferation process in breast cancer we tested a subset of the
HP vs. LP differentially miRNAs using high-throughput lysate
microarray (LMA) screening technology [28]. For that purpose,
miRNAs were transfected into the cell lines MCF-7 (luminal-like,
ER-positive) and BT-474 (ERBB2-amplified, ER-positive, TP53
mutated) using a library of pre-miR constructs. After 48 h and
72 h incubation, the cells were lysed and the lysates were printed
onto nitrocellulose-coated slides and stained with a specific
antibody against Ki67 to assay the effect of miRNA on
proliferation (see Materials and Methods). Of the 123 miRNAs
identified as LP vs. HP differentially expressed, 61 were
represented in the LMA/Ki67 screen. Of these 13 showed a
matching effect on Ki67 protein level in the tested cell lines
(Figure 5A, Table S7). Among the miRNAs that were down-
regulated in HP samples we found the strongest matching effect
for miR-449a (MCF-7), miR-154 (BT-474) and miR-34c-5p
(MCF-7 and BT-474) (Figure 5A and B). In the MCF-7 cell line
over-expression of miR-342 leads to reduced proliferation, which
is in line with its low expression in TP53 mutated samples. Of
those over-expressed in the HP samples we found the strongest
matching effect for miR-146b (MCF-7) and miR-150 (BT-474),
but we also see an agreement for miR-19a and miR-130b
(Figure 5A and B and Table S7). Among the miRNAs with
opposite expected effect on Ki67 levels we note miR-18a/b and
let-7b/c/e (See Table S7 for complete list).
miR-29c is associated with cell adhesion/extra cellular
matrix
The tumors studied here have previously been classified into
four classes based on a signature of extracellular matrix (ECM)
genes [29]. Strong degree of differential expression is seen at the
miRNA level between ECM1 and ECM3 as well as between
ECM1 and ECM4. We focused on the ECM1 and ECM4 classes
(23 and 16 samples, respectively) and identified 47 differentially
expressed miRNAs (at 5% FDR, Figure S3A). miR-29c, shown in
previous sections to be down regulated in basal-like samples as
compared to luminal-A samples, was found to be the most
differentially expressed miRNA between the two ECM classes
(TNoM p,3E-5, lower in ECM1, Table S8). We used the
TargetScan prediction tool [30] to rank all genes according to
their miR-29c target prediction scores. The top predicted targets
of miR-29c were found to be enriched with genes related to the
cell-adhesion GO-term (Figure S4). Further supporting its direct
role in our cohort, we found miR-29c targets as well as cell
adhesion genes to be significantly anti-correlated with miR-29c
expression (mHG p,2E-11 and mHG p,2E-13, respectively; see
Figure S3B and C and Materials and Methods).
miRNAs related to survival
For all 489 miRNAs, we ran univariate Cox regressions to
predict survival. The top 9 miRNAs resulted in 37% FDR (Table
S9).
High expression levels of the immune module have previously
been associated with better survival in ER-/HER2- patients [31].
In agreement with the strong association of miR-150 with genes
related to the immune response, we found high expression of miR-
150 alone to be predictive of better prognosis (log-rank p,0.085)
within the corresponding set of patients in our cohort, namely the
ER-/non-ERBB2 enriched patients (Figure S5).
Discussion
In this work we introduce an extensive analysis of miRNA
expression in 101 tumor samples from breast cancer patients. We
show that miRNA expression alone is sufficient to distinguish
luminal-A from basal-like samples, two types that represent
different degrees of aggressiveness of the disease. Specifically, the
oncogenic miR-17-92 module is shown to be distinctly over-
expressed in highly proliferative samples including the basal-like
samples, which are also characterized with high frequency of TP53
mutations. Recently we have shown that the miR-17-92 module is
repressed by wild-type TP53 in an E2F1-mediated manner [27].
Our integrated analysis supports the E2F association with the
miRNA cluster. Other over-expressed members of the cluster,
such as miR-17-5p/miR-20, have been linked to the regulation of
Figure 3. Expression of miR-150 and its mRNA correlates. (A) The samples are ordered according to the expression levels of miR-150 for that
sample. The absolute signal intensities of miR-150 are presented in the top panel. The top 50 correlated genes are sorted from top to bottom. The
color in the bar beneath the heatmap indicates the different subtypes. As can be seen many luminal-A samples have low levels of miR-150 expression
though no clear cut can be deduced to separate the luminal-A samples from the rest of the subtype samples. (B) Graphical representation of GO-term
enrichment of genes positively correlated to miR-150. The strongest enrichment is seen for the ‘‘immune response’’ (p,1.2E-147) term. The graph is
color coded according to degree of enrichment. Figure obtained using the GOrilla web tool [62].
doi:10.1371/journal.pone.0016915.g003
Integrated RNA Analysis of Human Breast Tumors
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16915cell proliferation through a Cyclin D1 regulatory feedback loop
[32] and through the inhibition of AIB1 translation [33] in breast
cancer. miR-18a directly targets ESR1 [28] and has been shown
to promote estrogen receptor alpha (ESR1) dependent prolifera-
tion in hepatocellular carcinoma cells [34]. In addition we have
recently observed that the miR-18 cluster is over-expressed in a
panel of samples from various cancers types [20]. miR-18a/b may
therefore be an important contributor to the different overall gene
expression profiles that distinguish between malignant to non
malignant tumors, specifically ER positive tumors.
We further explore and characterize the miRNA expression
signature that distinguishes between basal-like and luminal-A
samples, known to be reciprocal with respect to mRNA expression
and clinical properties. We show that miR-9/9* are markers for
aggressive tumors, being expressed specifically in the basal-like
tumors. miR-9/9* are over-expressed in c-Myc induced mouse
mammary tumors [35], as well as in brain [36] and ovarian
primary cancers [37] which points to a more general role in cancer
progression for this miRNA. In our cohort we see a positive
correlation between miR-9 and c-Myc (Pearson’s r=0.22) and
Figure 4. Proliferation associated miRNAs. The panels show miRNAs that are both positively and negatively associated with proliferation in in
vivo profiling from tumors. (A) Immunohistochemistry staining of Ki67 of tumors scored as highly proliferative (HP, sample 267) and low proliferative
(LP, sample 570). The right panel shows the signal distribution in the 101 samples for three selected miRNAs, miR-142-3p, miR-19a, and 449a, with
signal intensities for sample 570 (red dot) and 627 (green dot) highlighted. (B) Volcano plot of all miRNAs with TNoM p-value of differential expression
against fold change differences in low (24 samples) versus high (35 samples) proliferation groups. Pink dots represent significant miRNAs (p,0.001).
Left part contains miRNAs that are up-regulated in highly proliferative samples and right part down-regulated miRNAs. (C) The plot shows the scores
for each miRNA, where each miRNA is represented by a dot. On the Y-axis differential expression score is –log(p-value) if miRNA is up-regulated and
log(p-value) if miRNA is down regulated, thus assigning positive and negative scores according to differential expression between the high and low
proliferative groups. Significance of differential expression is calculated using TNoM as described in Materials and Methods. ‘‘Cell-Cycle’’ (CC) score is
–log(p-value) if the CC genes are enriched within the genes positively correlated to the miRNA, and log(p-value) if the CC genes are enriched within
the genes negatively correlated to the miRNA. p-value for CC enrichment is calculated using the mHG statistic as described in Materials and Methods.
doi:10.1371/journal.pone.0016915.g004
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the two factors in breast cancer.
In addition to tumor subtypes we also analyzed the miRNA
expression signature with respect to other molecular characteristics
of the tumors like TP53 mutations. TP53 mutant samples largely
overlap the basal-like samples and the ER-negative samples.
Therefore the majority of the miRNAs found to be over-expressed
in basal-like samples were also over-expressed in TP53 mutated
samples and ER-negative samples and vice versa. Among the
differentially expressed miRNAs we find miR-34c which is a direct
transactivation target of TP53 [38] and miR-18a/b which targets
ER [28]. The let-7 family and miR-342 exhibit, in our cohort, a
more significant differential expression between TP53 mutational
statuses than between ER statuses or tumor subtypes. These
miRNAs have previously been linked to tumorigenesis [39,40] and
further characterization is needed to understand their relationship
to TP53 and ER. Although miR-34a was previously shown to
regulate TP53, we do not see it differentially expressed in the
context of TP53 mutational status which might indicate a lack of
feedback loop in this regulation.
We introduce several new approaches to analyze miRNA and
mRNA expression data in an integrated manner using a systems
biology approach. In particular we assess the enrichment of
various gene sets amongst the genes correlated/anti-correlated to
the expression levels of a pivot miRNA. Our straight forward
approach allows to comprehensively associate miRNAs to
biological processes in a statistically sound and functionally
relevant manner. Thus, our approach leads us to additional
insight into the role of miRNAs in breast cancer and enables the
identification of key players. Other approaches of data integration
[41,42] are aimed at finding a set of miRNAs and a set of mRNAs
that are expressed in a concerted manner either in a subset of the
samples or in the entire cohort. We note that while these
approaches are computationally sophisticated they are not driven
by functional relevance.
In particular we point to a significant association of many
miRNAs to the cell-cycle module. Our methodology also shows
that miRNAs over-expressed in proliferative samples, are corre-
lated to positive regulators of cell-cycle. Similarly, miRNAs under-
expressed in proliferative samples are correlated with negative
regulators of cell-cycle. The relationship between enrichment of
these gene sets and proliferation related differential expression is,
in general, monotone, as depicted in Figure 4. This monotonicity
further demonstrates the sensitivity of our approach in terms of
detecting miRNA association to biological processes.
The integrated analysis also revealed the association of several
miRNAs to the immune response module, a major biological
process closely associated with cancer progression and develop-
ment [43]. We found miR-150, as well as miR-155 and miR-142,
to have strong positive correlation to the immune response
module. As miRNAs are considered to be negative regulators of
expression the positive association of miR-150 to the immune
response indicates that miR-150 is not a direct regulator of this
process but rather a part of the immune response transcriptional
program. Several studies have identified miR-150 to be involved in
controlling B-cell differentiation by targeting the transcription
factor c-Myb [44,45,46]. In our dataset (data not shown) we see an
inverse correlation (Pearson’s r = 20.18) between Myb and miR-
150 expression levels which might point to a similar regulation
pathway of immune response in breast cancer. Immune response
was previously linked to clinical outcome in ER-/HER2- samples
[31], and in accordance with its strong association to the immune
response module we see that miR-150 can predict clinical outcome
in our ER-/HER2- samples. This makes miR-150 a good marker
for the activity of the immune response in breast cancer samples,
as high expression of miR-150 is associated with active immune
response and better prognosis. Since we could not find any
association of miR-150 to any of the known breast cancer subtypes
we propose that its expression can act as a mean for classifying
breast cancer samples based on immune response. However, more
Figure 5. Proliferation assay in miRNA transfected cell-lines. The panels show miRNAs that are both positively and negatively associated with
proliferation in transfected cell-lines. (A) list of miRNAs that showed a significant effect on proliferation in cell-lines with a corresponding differential
expression in tumors. (* indicates opposite effect in MCF-7 and BT-474). (B) Lysate microarray (LMA) screening of MCF-7 and BT-474 cells transfected
with 20 nM human Pre-miR
TM miRNA Precursor library v2. Ki67 readout after 48 and 72 hours. The two miRNAs from panel A with strongest positive
and negative effect on proliferation for each cell line are shown (see Table S7 for complete list)
doi:10.1371/journal.pone.0016915.g005
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between miR-150 and the immune response as well as between
miR-150 and prognosis.
We further examined the involvement of miRNAs in regulating
cell proliferation. Comparing the highly proliferative (HP) samples
to the low proliferative ones (LP) we discovered a distinct miRNA
expression signature. Specifically, we validate in vivo the associa-
tion of the miR-17-92 module to proliferation in breast cancer, in
agreement with the same association observed in tumor cell lines
[47]. In addition, we find miR-199a and miR-214 to be
significantly down regulated in HP samples, specifically in ER-
negative samples. Both miRNAs reside on 1q24.3 and were
previously shown to be downregulated in ER- samples [24] and to
induce cell survival by targeting PTEN and subsequently
activating the Akt pathway in ovarian cancer [48]. Overall, we
observed a higher number of miRNAs with lower expression in
HP than in LP samples. This is consistent with the higher number
of lower expressed miRNAs in ER-negative than in ER-positive
tumor samples observed by others [24,49].
As differential expression does not imply causality, we carried
out functional assays to validate and characterize the effect of
individual miRNAs on proliferation. In the cases of miR-130b and
miR-19a, up regulated in HP (with positive correlation with the
cell-cycle genes), and miR-449a, miR-299, miR-154 and miR-145,
downregulated in HP (with negative correlation with the cell-cycle
genes), the effect of miRNA over-expression on proliferation was
confirmed in cell lines. We therefore propose that for these
miRNAs the association with proliferation is not only manifested
in the transcriptomics level but rather they are likely to be drivers
of the process. The strongest effect was seen for miR-449a. In
prostate cancer cell lines miR-449a was shown to have growth
suppressing activity partly through inhibition of HDAC-1
expression [50]. The expression patterns of miR-449a and of
HDAC-1, in our cohort, are anti-correlated (Pearson’s r=20.26)
and it might be that the mechanism is similar in breast cancer. It is
therefore of interest to characterize its relationship to proliferation
and assess its therapeutic potential. Consistent with our findings,
this recent study [50] also reports miR-145 to inhibit proliferation.
We note that Blenkiron et al. [24] observed higher expression of
miR-145 in luminal-A samples.
There is an apparent disagreement between the functional
proliferation assay results for several other miRNAs (e.g. miR-
18a/b). Since association does not imply causality this apparent
disagreement is, in fact, expected. In addition, this disagreement
can be a result of the complexity of transferring observations from
individual cell-lines to clinical tumor cohorts. For the case of miR-
18a/b we note that [27] showed that this miRNA and the miRNA
cluster it resides in (miR-17-92 cluster) are activated by E2F.
Therefore, it is reasonable to expect its expression level to be
driven by the cell-cycle process rather than to be a determinant of
that process.
Analyzing miRNA expression with respect to extracellular
matrix component signature of the studied cohort, we found miR-
29c to be the most prominently differentially expressed. It is
under-expressed in the ECM1 class and over-expressed in the
luminal-A subtype. Predicted targets of the miR-29 family are
enriched with genes associated with cell-adhesion and show
significant anti-correlation to the expression of miR-29c which
points to a direct involvement of miR-29c in regulating cell-
adhesion. Over-expression of the miR-29 family was shown to
revert aberrant methylation patterns in lung cancer [51], and
recently it was shown that miR-29 can induce apoptosis in a TP53
dependent manner [52]. In our cohort we also found miR-29c to
be significantly under-expressed in proliferative samples (Table
S5), which may suggest breast tumor suppressive activity mediated
by the regulation of the ECM related genes.
We have run univariate Cox analysis to assess the association of
miRNAs and survival in the entire cohort. We have not found any
significant association of any of the tested miRNAs, after
correcting for the multiple testing. We do find miR-150 to be
associated to survival in part of the cohort as described above.
Conclusion
We introduce a dataset of mRNA and miRNA expression
profiles measured in a well studied patient cohort. We show that
miRNAs can distinctly differentiate between tumor subtypes and
various clinical sub-classifications. In addition, we present
experimental support linking some miRNAs to proliferation.
Finally, we show that miRNAs can act as reliable proxies to the
activity of known biological processes related to breast cancer
progression such as cell-cycle, immune response and cell adhesion.
Materials and Methods
Patient characteristics and classifications
The 101 breast cancer patients in this study are part of a cohort
previously described [53]. The study was approved by the
Norwegian Regional committee for medical research ethics,
Health region II (reference number S-97103). All patients have
given written consent for the use of material to research purposes.
Total RNA isolation was performed using TRIZOL (Invitrogen)
as described previously [54]. The mRNA expression derived
subtype classification has previously been performed and present-
ed [8]. The same is true for the extracellular matrix (ECM) based
classification [29].
Expression profiling
miRNA microarray hybridization. miRNA profiling from
total RNA was performed using Agilent Technologies ‘‘Human
miRNA Microarray Kit (V2)’’ according to manufacturer’s
protocol. Scanning on Agilent Scanner G2565A and Feature
Extraction (FE) v9.5 was used to extract signals. Excluding two
samples, experiments were performed using duplicate hybridiza-
tions (99 samples) on different arrays and time points. miRNA
signal intensities for replicate samples were averaged and log2
transformed. The expression levels were normalized to the 75
th
percentile. That is, the expression levels in each sample, i, were
multiplied by a constant, ci, such that the 75
th percentile of the
expression levels in that sample will equal to a constant c – the 75
th
percentile in the entire dataset. miRNA expression status was
scored as present or absent for each gene in each sample by default
settings in FE v9.5. miRNAs in samples that were run in replicates
were considered present if scored in one of the two arrays. The
microarray contains probes for 76 viral and 723 human miRNAs
(based on miRBASE v10.1). We filtered out all miRNAs that were
detected in less than 10% of the samples. This filtering resulted in
489 miRNAs considered to be expressed in this set of human
breast tumors and used in further analysis steps. For these
miRNAs, all expression values were used for further analysis.
Thus, no missing values were used. The miRNA expression data is
MIAME compliant and have been submitted to the Gene
Expression Omnibus (GEO) with accession number GSE19536.
miRNA expression using RT-PCR. Quantification of nine
selected mature miRNAs was performed on 20 samples with
TaqManH MicroRNA Assays (Applied Biosystems). The miRNAs
selected for this validation were miR-17-5p, miR-18a, miR-18b,
miR-19a, miR-29c, miR-34c-5p, miR-142-3p, miR-150 and miR-
449a, and the endogenous control used was RNU6B. RT-PCR
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dation. In brief, 10 ng of total RNA was reverse transcribed using the
TaqManH MicroRNA Reverse Transcription kit (Applied Biosys-
tems) with miRNA specific RT-primers (Applied Biosystems).
Quantitative Real-Time PCR was performed following the
manufacturer’s recommendation in triplicates on a 7900 HT Fast
Real-Time PCR System (Applied Biosystems) with a standard
absolute quantification thermal cycling program and using the SDS
2.3 software (Applied Biosystems) to determine the cycle threshold
(Ct). The endogenous control was used for normalization. Pearson
correlation was used to investigate the correlation between the
microarray and RT-PCR quantification approaches (Figure S6).
mRNA microarray hybridization. mRNA profiling from
total RNA on the same (TRIZOL extracted) samples were
performed on an Agilent catalogue design whole human genome
4x44K one color oligo array. Scanning was performed on Agilent
Scanner G2565A and signals were extracted using Feature
Extraction v9.5. Data were log2 transformed, non-uniform spots
were excluded. Population outliers were excluded when averaging
replicated probes. Probes that are missing on more than 10 arrays
were excluded. Quantile normalization was performed in R using
normalizeBetweenArrays from the LIMMA library [55] and
missing values imputed using LLS imputation (R: LLSimpute from
the pcaMethod library with k=20) [56]. The mRNA expression
data is MIAME compliant and have been submitted to the Gene
Expression Omnibus (GEO) with accession number GSE19783.
Statistical analyses
Hierarchical clustering. Hierarchical clustering was carried
out using MeV data analysis tool (ver. 4.4, http://www.tm4.org/).
The 100 miRNAs with highest expression variance were selected.
Average linkage clustering was carried out on both samples and
miRNAs,using Spearmancorrelation asa distancemeasure.miRNA
expression values were normalized for visualization purposes.
Differential expression. The assessment of miRNA
differential expression when considering the comparison of any
two classes was performed using TNoM (Threshold Number of
Misclassifications) [57,58]. Briefly, TNoM counts the number of
misclassified samples, according to the given gene expression
pattern, and uses combinatorics to compute the exact a-parametric
p-value. To assess which genes are significant we used the FDR
method [25] based on the exact p-value calculations for TNoM.
Enrichment analysis. To assess the enrichment of a fixed
gene set within a ranked list of genes we use the minimum
hypergeometric (mHG) statistics [59]. Briefly, consider a ranked list of
genes: g1,…,gN and a given subset of genes H. We define a label
vector l = l1,…,lN M [0, 1]
N according to whether the ranked
genes belong to H. Namely, li = 1 iff gi M H, for every i. The mHG




















mHG p-values presented herein are exact and do not require
correction for multiple thresholds tested [59].
In this paper we use GO terms [60], MSigDB sets [61] and
miRNA target sets [30] to define different sets of genes (playing the
role of H above). GO enrichment analysis was performed using the
GOrilla web tool [62], which takes as input a ranked list of genes.
The following ranking schemes are used in the analyses
performed in this study (see Figure S7): (A) Differential expression
– using TNoM or other scores, as described above. (B) Correlation
to pivot miRNA – for a specific miRNA, called the pivot miRNA,
mRNAs were ranked according to the correlation of their
expression pattern across the entire cohort (101 samples) to the
pivot miRNA expression pattern. To obtain the results presented
here we used Spearman’s correlation. (C) miRNA target
prediction – for a specific miRNA, genes were ranked according
to how likely they are to be targeted by the miRNA. Context score
values, taken from TargetScan V5.1 target prediction tool [30],
were used as prediction scores.
In the case of miRNA target enrichment, the genes were ranked
according to their anti-correlation to a pivot miRNA. The top
2000 targets of the pivot miRNA were then tested for enrichment
amongst the top anti-correlatees. Enrichment in this case indicates
a significant anti-correlation between the expressions of the
miRNA and the expression of its targets.
Survival analysis. The univariate Cox scores for each of the
489 miRNAs was calculated using SAS. The log-rank calculation
for miR-150 was performed using Matlab version 2008b
(Mathworks, Inc).
Assessment of proliferation
Formalin-fixed paraffin-embedded tissue was available from 93
of the 101 patients as part of a Tissue Micro Array (TMA). Briefly,
the TMA was composed of three 0.6 mm cores from each of the
tumor specimen assembled in a recipient paraffin block using a
manual device from Beecher Instruments, Silver Spring, USA.
Immunohistochemistry (IHC) was performed with antibody
directed towards Ki67 (MIB1 from DAKO, diluted 1:100) using
the Envision+ detection system (DAKO). The slides were scored
visually using a conventional microscope and grouped by level of
positivity into three groups; negative (#1% stained cells),
moderate (1-10%) and high (.10%) regardless of intensity.
Samples with no interpretable cores were excluded (three patients).
The highest value was used if the three cores from a patient
showed discrepant scores. In total, 90 patients had interpretable
Ki67 IHC staining; 29 were classified as negative, 39 classified as
moderate and 22 classified as high Ki67 (summary of scoring
results presented in Table S10) [53].
Whole tissue sections were available from 92 patients, and the
mitotic count was assessed by microscopy as part of estimating the
histological grade. Briefly, the number of mitoses in 10 high power
fields were counted and the samples were classified as having low
(0–5 mitoses), moderate (6–11 mitoses) or high (.11 mitoses)
mitotic index (MI). Out of 95 samples, 39 had low MI, 21 had
moderate MI and 32 had high MI.
Proliferation groups were created by dividing the samples in two
groups. Samples with a high score on both Ki67 and mitotic index
or high and moderate were considered highly proliferative (24
samples). Samples that scored low/negative on both Ki67 and
mitotic index or low and moderate were considered weakly
proliferative samples (35 samples) (Table S10).
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MCF-7 cells were obtained from Interlab Cell Line Collection
(ICLC, Genova, Italy) and BT-474 from American Type Culture
Collection (ATCC, Manassas, VA, USA). For lysate microarray
(LMA) screening, the MCF-7 and BT-474 cells were transfected
with 20 nM human Pre-miR
TM miRNA Precursor library v2
(Ambion Inc., Austin, TX) as previously described [28]. There-
after, the cells were lysed and printed on nitrocellulose-coated
microarray FAST
TM slides (Whatman Inc., Florham Park, NJ).
Ki67 was detected by staining the slides with Ki67 antibody
(#M7240, Dako, Glostrup, Denmark) followed by exposure to
Alexa Fluor 680 -tagged secondary antibody (Invitrogen Inc.,
Carlsbad, CA). For total protein measurement, the arrays were
stained with Sypro Ruby Blot solution (Invitrogen Inc.). The slides
were scanned with Tecan LS400 (Tecan Inc., Durham, NC)
microarray scanner and Odyssey Licor IR-scanner (LI-COR
Biosciences, Lincoln, NE) to detect the Sypro and Ki67 signals,
respectively. Array-Pro Analyzer microarray analysis software
(Median Cybernetics Inc., Bethesda, MD) was used for analyzing
the data. For each miRNA the signal intensity was normalized to a
negative control miRNA (z-score). miRNAs that gave at least one
hit with a z-score .2o r,-2 as well as both z-scores .1o r,-1 at
both 48 h and 72 h were considered as having an effect on
proliferation.
Supporting Information
Figure S1 Expression profiles of miR-9*, miR-29c and
miR-190b in subtypes. Expression profiles (signal intensities) of
miR-9*, miR-29c and miR-190b ordered by subtypes. Note that
Y-axes in different panels are in different scales.
(EPS)
Figure S2 Proliferative miRNAs versus cell-cycle relat-
ed enrichments. The plot shows the scores for each miRNA,
where each miRNA is represented by a dot. On the Y-axis the
differential expression score is –log(p-value) if the miRNA is
upregulated and log(p-value) if the miRNA is down regulated,
yielding positive and negative scores according to differential
expression between the high and low proliferative groups.
Significance of differential expression is calculated using TNoM
as described in Materials and Methods. (A) ‘‘Positive regulation of
mitotic cell cycle’’ score is –log(p-value) if CC genes are enriched
in the miRNA positively correlated genes, and log(p-value) if CC
genes are enriched in the miRNA negatively correlated genes. P-
value for CC enrichment is calculated using the mHG statistic as
described in Materials and Methods. Here CC genes are those
annotated in GO as ‘‘positively regulation of mitotic cell cycle’’. (B)
‘‘Negative regulation of S phase of mitotic cell cycle’’ scores are
calculated in the same manner as ‘‘Positive regulation of mitotic
cell cycle’’ scores. The difference is in the definition of CC genes.
Here we use genes annotated in GO as ‘‘Negative regulation of S
phase of mitotic cell cycle’’.
(EPS)
Figure S3 Association of miR-29c with extracellular
matrix. (A) Extracellular matrix miRNA differential expression.
miRNAs ordered by significance of differential expression between
two reciprocal extracellular matrix classes ECM1 and ECM4. For
visualization expression values of each miRNA were linearly
stretched. miR-29c shows the highest significance of differential
expression between the two classes (TNoM p,4E-5, see Table S8 for
full list). (B) miR-29c is anti-correlated to its mRNA targets. All
mRNAs were ranked according to their anti-correlation to miR-29c
expression profile. The absolute signal intensities of miR-29c are
presented in the top bar. The top 50 anti-correlated genes are ordered
from top to bottom. We find a significant enrichment of miR-29c
targets, as derived from TargetScan V5.1, in the anti-correlated gene
ranking (mHG p,3E-11). The color bar beneath the heatmap
illustrates the different subtypes. (C) GO enrichment in miR-29c anti-
correlated genes. The figure depicts the GO enrichment result, as
carried out by GOrilla [62]. We observed an enrichment of terms
related to extracellular matrix (e.g. cell-adhesion).
(EPS)
Figure S4 GO enrichment in miR-29c targets. Target
prediction context scores of miR-29c were taken from TargetScan
V5.1. We find enrichment of several GO terms in the high scoring
genes, with respect to miR-29c targets, using GOrilla web tool
[62]. The graph is color coded according to degree of enrichment.
(EPS)
Figure S5 miR-150 and survival. ER-/non-ERBB2 enriched
patients from our cohort were divided to two groups: patients with
high expression of miR-150 (above the average in the entire cohort
which was 1041) and patients with low expression of miR-150
(below average). Using a log-rank test we found that high
expression of miR-150 is predictive of better prognosis (log-rank
p,0.085) in the ER-/non-ERBB2 enriched patients.
(EPS)
Figure S6 RT-PCR analysis of miRNA expression. Each
panel displays Agilent expression (vertical axis) versus negative
TaqMan expression (horizontal axis) for a miRNA on all 20
samples. Two lines are shown in each panel: the least squares fit to
the data (green) and a robust regression line found by iteratively
reweighted least squares with a bisquare weighting function
(magenta). Pearson’s correlation coefficients and corresponding p-
values are shown above each panel.
(EPS)
Figure S7 Workflow. Schematic overview of the data analysis
methods applied. (A) Differential expression – using TNoM or other
scores. (B) Correlation to pivot miRNA – for a specific miRNA,
called the pivot miRNA, mRNAs were ranked according to the
correlation of their expression pattern across the entire cohort (101
samples) to the pivot miRNA expression pattern. (C) miRNA target
prediction – for a specific miRNA, genes were ranked according to
howlikelytheyaretobetargetedbythemiRNA.A,BandCalllead
to ranked lists of genes which are analyzed using the mHG method.
(EPS)
Table S1 Characterization of the samples.
(XLS)
Table S2 miRNAs differentially expressed between
basal-like and luminal-A like samples.
(XLS)
Table S3 miRNAs differentially expressed between
TP53 WT and mutant and between ER-positive and
ER-negative.
(XLS)
Table S4 Enrichment levels of miRNA-GO associations.
(XLS)
Table S5 miRNAs significantly associated with prolif-
eration.
(XLS)
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tive and ER-negative samples.
(XLS)
Table S7 LMA screen of Ki67.
(XLS)
Table S8 miRNAs differentially expressed between
ECM1 and ECM4.
(XLS)
Table S9 miRNAs associated with survival.
(XLS)
Table S10 Proliferation scoring scheme.
(XLS)
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